A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
LMU Munich: Prospective study shows the suitability of a semi-automatic approach to assess changes in prostate MRI after prostatic artery embolization
A prospective, monocentric study [1] conducted by Vanessa F. Schmidt and her colleagues at the University Hospital Munich (LMU) evaluated the…
Structure, Gather, and Share Data Faster with the mint Lesion™ Browser-Based Application
Whether in clinical routine, in clinical trials or in clinical research, mint Lesion™ is a reliable and strong supporter of its users’ individual…